Login / Signup

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.

Paul FeuerstadtThomas J LouieBret LashnerElaine E L WangLiyang DiaoJessica A BryantMatthew SimsColleen S KraftStuart H CohenCharles S BerensonLouis Y KormanChristopher B FordKevin D LitcofskyMary-Jane LombardoJennifer R WortmanHenry WuJohn G AuniņšChristopher W J McChalicherJonathan A WinklerBarbara H McGovernMichele TrucksisMatthew R HennLisa von Moltke
Published in: The New England journal of medicine (2022)
infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection. The observed safety profile of SER-109 was similar to that of placebo. (Funded by Seres Therapeutics; ECOSPOR III ClinicalTrials.gov number, NCT03183128.).
Keyphrases
  • healthcare
  • palliative care
  • clostridium difficile
  • clinical trial
  • phase iii
  • quality improvement
  • pain management
  • study protocol
  • open label